Background {#Sec1}
==========

HBV and HCV infections continue to be global health concerns, affecting over 500 million people worldwide \[[@CR1]\]. India remains a country with a high burden of viral hepatitis. It is estimated that the prevalence of HCV is \~0.5--1.0 % and \~2--8 % for HBV \[[@CR2]--[@CR6]\]. While infection rates are high, engagement with the healthcare system is limited in part by access to healthcare systems and individual knowledge of disease transmission, natural history, and treatment options \[[@CR7], [@CR8]\]. With the availability of a preventative vaccine for HBV and effective therapies for HBV and HCV, improving interactions with healthcare systems may improve overall health for those infected with HBV and HCV.

Hepatitis knowledge has been demonstrated to be associated with disease management and outcomes, with improved management and outcomes among those with increased knowledge of the disease \[[@CR8], [@CR9]\]. Further, as knowledge of transmission improves, rates of disease screening and incidence have been shown to decrease \[[@CR10]\]. There is a lack of data, however, assessing the overall knowledge of disease for viral hepatitis and evaluating associations with clinical parameters. Assessing the current status of disease knowledge is important for demonstrating knowledge gaps that ultimately will be useful for designing specific public health interventions.

In this study, we assess disease knowledge of HBV and HCV in India using a series of questions administered to 500 HBV and 500 HCV patients throughout India. The goals of this study are to (1) characterize and validate answers to a series of questions adapted from the NHANES questionnaire, (2) identify differences in knowledge awareness of disease between HBV- and HCV-infected patients, and (3) identify associations with clinical parameters.

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

A total of 500 HBV and 500 HCV patients were recruited from 19 centers geographically distributed across India. Practice types included community clinics, government hospitals, government assistance programs, and private practices. At a single study visit, a survey was administered and clinical laboratory tests were performed. The surveys collected information on participants' sociodemographic characteristics, hepatitis-related knowledge, experiences, and behaviors and were subsequently linked to participants' laboratory and clinical measures. This study was approved by the Institutional Review Boards governing the participating centers.

Description of study variables {#Sec4}
==============================

India Hepatitis Knowledge Index {#Sec5}
-------------------------------

We used ten hepatitis survey questions adapted from the NHANES follow-up questionnaire for hepatitis C to create the India Hepatitis Knowledge Index (IHKI) \[[@CR11]\]. These ten questions assessed patient knowledge of hepatitis disease transmission, natural history, treatment, and prevention options. HBV and HCV patients were only asked about knowledge regarding their specific hepatitis type.

We conducted a factor analysis by hepatitis type to assess whether items on the knowledge scale hold together as one or more constructs or measures of knowledge. Only one distinct factor of knowledge was identified in factor analysis. For each hepatitis type, a Cronbach's alpha (*α*) for the reliability of our ten scale items to assess the adequacy of scale reliability was performed. We created IHKI by hepatitis B or C patients. The index score was the number of correct questions (index range 0--10).

Clinical laboratory tests/values {#Sec6}
--------------------------------

At the clinic visit, clinical laboratory assessments were made including AST, ALT, albumin, bilirubin (total and direct), INR for prothrombin time, GGT, and creatinine. Viral factors evaluated were HCV RNA and HCV genotyping (for those with HCV infection) and HBV DNA, HBeAg, and anti-HBeAg (for those with HBV infection). MELD and APRI calculations were performed for all patients.

For sensitivity analyses, we categorized patients into high ALT or low ALT using separate cutoffs for males and females. For males, high ALT was defined as ALT ≥90 and low ALT was defined as ALT \<90; for females, high ALT was defined as ALT ≥57 and low ALT was defined as ALT \<57. We also categorized HBV patients into high and low viral counts (high viral load ≥2000 IU/ml, low viral load \<2000 IU/ml).

Covariates {#Sec7}
----------

We included age, sex, duration of infection, type of healthcare practice, geographic region of India, and hepatitis experience as covariates in the analysis. All covariates were collected from the patient survey. Age was measured continuously. Duration of hepatitis was defined as \<1 year, 2--5 years, and \>5 years. Patients were asked at what type of healthcare practice they received most of their regular care (private practice, community clinic, government hospital/program). The location of participating centers was classified into four distinct regions of India (i.e., north, south, west, and east).

A summary measure of personal experiences with hepatitis was calculated from three survey questions and used to capture previous exposure to hepatitis as a possible predictor of knowledge and clinical outcomes. Personal experience with hepatitis was calculated from questions asking whether the respondent had family members with hepatitis, whether a family member had died from hepatitis, and whether the respondent lived in a community that spoke openly about hepatitis (yes/no). One point was given for every question where the patient answered yes (response range 0--3). The options "refused to answer" and "don't know" were available for all survey questions.

Statistical analysis {#Sec8}
--------------------

We assessed associations of hepatitis type, clinical values, and knowledge scores by patient sociodemographic factors using chi-square tests and one-way analysis of variance tests appropriate for our categorical and continuous measures of variables, respectively. We used Pearson correlations to examine associations between continuous sociodemographic characteristics and knowledge scores and median regression to examine associations between laboratory medians and sociodemographic characteristics.

Linear and logistic regressions were used to examine adjusted associations between sociodemographic characteristics and knowledge scores and between knowledge scores and clinical outcomes measured continuously and categorically. Age was centered in our models. Multivariate models for knowledge included age, sex, duration of infection, healthcare clinic type, and personal experience with hepatitis. Models for clinical outcomes included the hepatitis knowledge score.

In our sensitivity analysis we assessed how associations between knowledge and clinical outcomes varied for individuals with low and high ALT and for HBV patients with low and high levels of HBV DNA. All analyses were performed using STATA/SE 13.1.

Results {#Sec9}
=======

Among our sample of 1000 respondents, 1 (\<0.1 %) person had missing values for the knowledge score and was excluded from the analysis. In the analytic sample, overall the mean (SD) age was 41 (13) years, 72 % were male, and 75 % were Hindu, 6 % Muslim, 8 % Sikh, 9 % Christian, and 1 % some other religion (Table [1](#Tab1){ref-type="table"}). Over half of respondents reported hepatitis duration of less than 1 year, 28 % reported 2--5 years, 10 % reported having duration of more than 5 years, and 12 % refused to answer or did not know their duration of infection. Most respondents received primary care at private practices (61 %), community clinics (7 %), and government program (28 %), and 12 % refused to report or did not know the type of practice where they received care. Comparing HBV and HCV patients, those with HCV tended to be older (45 versus 37 years), more were females (34.4 versus 21.4 %), and more HBV patients reported a family history of hepatitis (24 versus 14 %). For both HBV and HCV patients the majority of patients had elevated ALT levels. Compared to HBV patients the HCV patients had laboratory values consistent with active or more advanced disease, including ALT (73 versus 50 U/l), albumin (3.8 versus 4.3 g/dl), and APRI (1.4 versus 0.4).Table 1Sociodemographic characteristics of study respondentsSociodemographic characteristicsHepatitis typeTotal study sampleHBVHCV*p* values\*All sample999499500Mean age in years (SD)41 (13)37 (12)45 (13)\<0.001Sex Female278 (28 %)106 (21 %)172 (34 %)\<0.001 Male721 (72 %)393 (79 %)328 (66 %)Religion Hindu754 (75 %)405 (81 %)349 (70 %)\<0.001 Muslim64 (6 %)38 (8 %)26 (5 %) Sikh81 (8 %)24 (5 %)57 (11 %) Christian93 (9 %)28 (6 %)65 (13 %) Other7 (1 %)4 (1 %)3 (1 %)Duration of hepatitis^a^ Less than 1 year505 (51 %)259 (52 %)246 (49 %)0.365 2--5 years275 (28 %)125 (25 %)150 (30 %) \>5 years100 (10 %)53 (11 %)47 (9 %) Refused/do not know119 (12 %)62 (12 %)57 (11 %)Healthcare practice type Private practice606 (61 %)303 (61 %)303 (61 %)0.686 Community clinic72 (7 %)36 (7 %)36 (7 %) Government program282 (28 %)137 (27 %)145 (29 %) Refused/DK39 (4 %)23 (5 %)16 (3 %)Geographic region of India North250 (25 %)125 (25 %)125 (25 %)1.000 South249 (25 %)124 (25 %)125 (25 %) West250 (25 %)125 (25 %)125 (25 %) East250 (25 %)125 (25 %)125 (25 %)Family history of hepatitis^a^ Yes194 (19 %)122 (24 %)72 (14 %)\<0.001 No/Ref/DK805 (81 %)377 (76 %)428 (86 %)Family death due to hepatitis^a^ Yes82 (8 %)49 (10 %)33 (7 %)0.064 No/Ref/DK917 (92 %)450 (90 %)467 (93 %)Community awareness of hepatitis^a^ Yes303 (30 %)147 (29 %)156 (31 %)0.549 No/Ref/DK696 (70 %)352 (71 %)344 (69 %)Clinical laboratory values, median (IQR) ALT, U/l50 (39--72)73 (50--112)\<0.001 Albumin, g/dl4.3 (3.9--4.5)3.8 (3.2--4.3)\<0.001 Total bilirubin, g/dl0.6 (0.4--1.0)0.8 (0.5--1.3)\<0.001 Direct bilirubin, mg/dl0.1 (0.1--0.2)0.2 (0.1--0.5)\<0.001 APRI0.4 (0.3--1.0)1.4 (0.6--3.1)\<0.001 MELD7 (6--9)8 (7--11)\<0.001\* *p* values were calculated using chi-square tests of association for categorical sociodemographic characteristics and analysis of variance for continuous sociodemographic characteristics^a^For HBV respondents, questions were asked in reference to HBV; for HCV respondents, questions were asked in reference to HCV

Correct responses to the ten knowledge questions are shown in Table [2](#Tab2){ref-type="table"}. Correct responses to questions ranged from 35 to 73 % for patients with HBV and 32--78 % for HCV. For most questions, there were no statistically significant differences in correct responses according to HBV versus HCV infection. Notably there were two questions regarding transmission (i.e., if sex with an infected partner is a risk factor for infection or whether hepatitis can be transmitted from mother to child through birth) and one question concerning the availability of a vaccine (all *p* \< 0.0001) in which more HBV patients answered the questions correctly. We summed the number of correctly answered knowledge questions to create a knowledge index. For each hepatitis type (i.e., HBV versus HCV), we found the adequacy of index reliability (HBV: *α* = 0.81; HCV *α* = 0.75), and the validity of the constructed knowledge composite score was determined by performing a factor analysis to identify the number of underlying factors measured by the knowledge questions. For both HBV and HCV, this analysis demonstrated a one-factor solution for both HBV and HCV patients (Supplemental table 1). We also evaluated the internal consistency of the index using Cronbach's alpha, which demonstrated a high index of reliability (HBV: *α* = 0.81; HCV *α* = 0.75). The IHKI score was set as the number of correct questions answered by an individual. The overall mean IHKI score for the entire population was 5.6 out of 10 (SD 2.8). Overall, HBV patients had higher knowledge scores than HCV patients (HBV scores 5.9 than HCV scores 5.3; *p* \< 0.001). Questions that appeared to contribute the most to differences in knowledge were those associated with transmission and vaccination.Table 2Hepatitis virus knowledge scale resultsHepatitis knowledge question^a^HBV correct response (*n* = 499)\
*N* (%)HCV correct response (*n* = 500)\
*N* (%)*p* value\*Can hepatitis B/C patients transmit the disease to others?295 (59 %)267 (53 %)0.069Is having sex with someone who suffers from hepatitis B/C a risk factor for getting infected with hepatitis B/C?268 (54 %)209 (42 %)\<0.001You can get hepatitis B/C by being born to a mother who suffers from hepatitis B/C when she gave birth252 (51 %)187 (37 %)\<0.001You can get hepatitis B/C by being pricked with a needle or sharp instrument or injecting illegal drugs with a needle that has hepatitis B/C-infected blood on it351 (70 %)362 (72 %)0.472You can get hepatitis B/C by receiving a blood transfusion from a hepatitis B/C-infected donor365 (73 %)389 (78 %)0.087If someone is infected with hepatitis B/C virus they will most probably carry the virus all their lives176 (35 %)172 (34 %)0.773Infection with the hepatitis B/C virus can cause the liver to stop functioning252 (51 %)250 (50 %)0.874Someone suffering from hepatitis B/C can look and feel fine307 (62 %)305 (61 %)0.865Is hepatitis B/C a treatable disease?345 (69 %)352 (70 %)0.664Is there a vaccine available for hepatitis B/C?351 (70 %)162 (32 %)\<0.001\* *p* values were calculated using chi-square tests of association^a^For HBV respondents, questions were asked in reference to HBV; for HCV respondents, questions were asked in reference to HCV

The average knowledge scores by sociodemographic characteristics are shown in Table [3](#Tab3){ref-type="table"}. Males and females with HBV had similar knowledge scores; however, for HCV, females had lower knowledge scores than males. Overall, respondents with a longer duration of infection and more personal family or community awareness of hepatitis had higher knowledge scores. In the overall population and for the HBV and HCV groups, there was a trend toward increased knowledge with a longer duration of infection, attending private practice, a family history of hepatitis and hepatitis-related death, and community awareness of disease. While not a predictor for either HBV or HCV, the overall group of patients showed a weak trend toward increased knowledge with lower age. Groups that performed the highest in the overall knowledge score included HBV patients with \>5 years of disease duration and HBV patients with a family death due to hepatitis.Table 3Sociodemographic characteristic and hepatitis knowledge scoreSociodemographic characteristicsOverall knowledge score*p* valueHepatitis typeHBV knowledge score*p* valueHCV knowledge score*p* valueAll sample999499500Age (correlation)−0.080.009−0.060.2170.21660.321Sex Female5.40.0606.00.9165.00.044 Male5.76.05.5Religion Hindu5.70.1196.00.16605.20.13 Muslim5.15.54.5 Sikh5.14.65.4 Christian6.06.25.9 Other6.46.36.7Duration of hepatitis^a^ Less than 1 year5.4\<0.0015.7\<0.0015.1\<0.001 2--5 years6.26.65.9 \>5 years6.676.0 Refused/DK4.34.44.1Healthcare practice type Private practice6.1\<0.0016.4\<0.0015.7\<0.001 Community clinic5.05.64.4 Government program5.05.34.8 Refused/missing4.14.23.9Geographic region of India North5.50.5165.60.1785.40.012 South5.86.15.4 West5.56.34.7 East5.75.75.7Family history of hepatitis^a^ Yes6.5\<0.0016.9\<0.0016.00.018 No/Ref/DK5.45.65.2Family death due to hepatitis^a^ Yes6.7\<0.0017.0\<0.0016.20.035 No/Ref/DK5.55.85.2Community awareness of hepatitis^a^ Yes6.2\<0.0016.7\<0.0015.8\<0.001 No/Ref/DK5.45.65.1\* *p* values were calculated using analysis of variance for categorical sociodemographic characteristics and Pearson correlations for continuous variables^a^For HBV respondents, questions were asked in reference to HBV; for HCV respondents, questions were asked in reference to HCV

Multivariate analysis did not show age or gender to be associated with knowledge scores for hepatitis B or C (Table [4](#Tab4){ref-type="table"}). For both HBV and HCV the duration of disease, type of healthcare practice, geographic regions in India, and personal experience with hepatitis were all associated with the mean knowledge score. Longer duration of infection, 2--5 years (for HBV, coefficient: 1.0 CI: 0.42, 1.6 and for HCV, coefficient: 0.8 CI: 0.28, 1.31) or more than 5 years (for HBV, coefficient: 1.1 CI: 0.29, 1.92 and for HCV, coefficient: 1.0 CI: 0.22, 1.79), was related to higher mean knowledge scores compared to respondents with less than 1 year since the time of diagnosis. Attending a community clinic (for HCV, coefficient: −1.43 CI: −2.32, −0.53) and government clinics (for HBV, coefficient: −0.085 CI: −1.44, −0.27 and for HCV, coefficient: −0.84 CI: −1.38, −0.31) was also associated with lower mean knowledge scores compared to those attending private practices. Increased personal experiences with hepatitis also were positively associated with increases in the knowledge score, and every additional experience with disease (0--3) increased the knowledge score by 0.82 (CI 0.51, 1.13). In adjusted models, patients who refused to answer or did not know the duration of infection or type of primary care clinic had the lowest knowledge scores compared to those with \<1 year disease duration and those visiting private practice clinics.Table 4Multivariate regression for predictors of knowledge scoresFactorsHBVHCV*b*SE*p* valueLCIUCI*b*SE*p* valueLCIUCIAge−0.010.010.21−0.030.01−0.020.010.10−0.030.00Sex MaleREFREF Female−0.070.300.82−0.660.52−0.460.240.06−0.930.01Duration of hepatitis^a^ Less than 1 yearREFREF 2--5 years1.010.300.000.421.600.800.260.000.281.31 \>5 years1.100.410.010.291.921.000.400.010.221.79 Refused/DK−0.900.400.02−1.68−0.12−0.830.370.02−1.55−0.11Healthcare practice type Private practiceREFREF Community clinic−0.420.490.39−1.380.54−1.430.460.00−2.32−0.53 Government program−0.850.300.00−1.44−0.27−0.840.270.00−1.38−0.31 Refused/missing−1.760.590.00−2.92−0.60−1.600.640.01−2.85−0.35Geographic region of India NorthREFREF South0.580.360.11−0.131.290.150.350.67−0.530.83 West0.690.350.050.001.39−0.620.340.06−1.280.03 East0.180.360.63−0.530.880.390.330.24−0.261.04Personal experiences with hepatitis^a,b^0.820.160.000.511.130.540.160.000.220.86_Cons5.100.350.004.425.795.430.340.004.776.09^a^For HBV respondents, questions were asked in reference to HBV; for HCV respondents, questions were asked in reference to HCV^b^Personal experiences were derived from questions asking if the respondent had family members with hepatitis, if any family member had died from hepatitis, and whether they lived in a community that spoke about hepatitis (yes/no). One point was given for every question where the patient answered yes (response range: 0--3)

Association with clinical parameters {#Sec10}
------------------------------------

In adjusted analysis, we found that increased knowledge was related to better clinical outcomes for hepatitis B patients (Table [5](#Tab5){ref-type="table"}). An increase in the IHKI score was related to lower MELD and APRI scores and lower INR, and bilirubin (total and direct) while associated with higher albumin levels. For patients with hepatitis C, no significant associations were seen although a trend toward lower MELD and higher albumin was seen with improved knowledge. In sensitivity analysis, we found the associations for hepatitis B to be strengthened for high HBV DNA and elevated ALT, a subgroup of hepatitis B patients who may have increased liver damage or more advanced liver disease (Supplemental table 2).Table 5Associations from adjusted linear or logistic regression of hepatitis knowledge and clinical outcomes by hepatitis typeContinuous clinical outcomesHBVHCV*b*SE*p* valueLCIUCI*b*SE*p* valueLCIUCIMELD−0.210.060.00−0.33−0.08−0.160.090.08−0.330.02Albumin0.020.010.010.010.040.020.010.070.000.04PT/INR−0.010.010.01−0.020.000.000.000.87−0.010.01Total bilirubin−0.210.060.00−0.33−0.08−0.010.030.75−0.070.05Direct bilirubin−0.130.040.00−0.22−0.05−0.010.020.64−0.040.02ALT−3.583.910.36−11.254.091.911.250.13−0.544.36Dichotomized clinical outcomesHBVHCVORSE*p* valueLCIUCIORSE*p* valueLCIUCIAPRI0.840.040.000.760.931.010.040.870.931.09High ALT0.950.040.200.871.031.010.040.840.941.09Models adjusted for age, sex, healthcare practice type, region of India, and personal experiences with hepatitis

Conclusions {#Sec11}
===========

In conclusion, our study demonstrates that a reliable scale of knowledge can be created using a simple survey that can be administered across diverse regions in India. Our results show that patients with HBV tend to have higher awareness of their disease and specifically have increased knowledge about modes of transmission and the availability of a vaccine as compared with patients with HCV. As might be expected, factors related to improved disease awareness included longer duration of infection and personal experience with hepatitis such as a family history of or family death from hepatitis. We did note that there was a trend toward an association of lower age and improved knowledge for the overall population, which may reflect an increase in knowledge in younger populations as a result of improved access to information. Of note, in the overall population religion, gender, and region of India were not associated with the knowledge score on univariate analysis. Finally, receiving care in a private practice setting was associated with higher knowledge scores for both HBV and HCV, which may be tied to socioeconomic status (SES). As SES was not assessed in this study, the reason for these improved scores among patients being seen in private practice cannot be definitively assessed.

Somewhat surprisingly, even with a limited set of questions evaluating knowledge, an association was seen with important clinical parameters including MELD, APRI, albumin, and bilirubin for HBV patients. This association may be interpreted to mean that individuals with lower knowledge about HBV tend to present in healthcare settings later and with more advanced disease. This is strengthened by the finding of an augmented effect among HBV patients with elevated ALT and HBV DNA. Given this is a single-visit, cross-sectional study, causality cannot be determined. These associations were more apparent for HBV, whereas only trends were noted for HCV. The reason for the lack of statistical significance among HCV patients may reflect higher values and variability in clinical laboratory results among HCV patients due to more advanced liver disease than in HBV patients or due to differences in sociodemographic predictors for contracting HCV versus HBV infection.

Despite the relatively large sample size and broad geographic distribution of the survey, there are several limitations of this study. While multiple centers were used for the study, sites were chosen based on feasibility rather than on a population-based sample, thereby limiting the generalizability of the findings to India and other populations. While broad concepts could be assessed with this simple survey, we were unable to evaluate more subtle differences in knowledge with only ten questions. This survey was also performed in conjunction with a blood draw, which may also introduce selection bias among patients being seen at these clinics. Finally, we did not collect the SES and educational levels of patients in our study, which may be important possible confounders for the results observed. While SES may be inferred from the practice type in which patients were seen, no definitive assessment of either SES or education was known, and no additional analysis was possible.

The findings of this survey demonstrate the overall low level of knowledge of basic disease transmission and natural history among patients in India and highlights the need for further education concerning HBV and HCV. Further, that lower disease knowledge may be associated with more advanced disease at the time of presentation may imply a tangible benefit of improved education among the population. With effective preventative and therapeutic options for HBV and HCV infection, improving disease knowledge may impact the overall disease burden in India.
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